Definium Therapeutics, Inc. (DFTX) — At an Investor and Analyst Day in New York, Definium Therapeutics detailed its DT120 (MM120) clinical and commercial strategy, reiterating three anticipated Phase 3 readouts across MDD and GAD in 2026.
The company also announced a program expansion with a planned Phase 3 Haven study in PTSD, enrolling roughly 200 patients randomized 1:1 to DT120 100 µg or placebo. The event underscored Definium's ambition to broaden LSD-based therapy across multiple psychiatric indications.
Source: stocktitan.net
For the rest of that week's sector news, read our week in review.